Inhaled insulin developer Dance Biopharm has announced the appointment of former Excelsior Medical President and CEO Steve Thornton to its board of directors. Thornton was also previously President and CEO of Bioniche Pharma and President of SkyePharma and has served on the boards of Halozyme Therapeutics and Pacira Pharmaceuticals.
Dance Biopharm Chairman and CEO John Patton commented, “Steve stands out as a pragmatic biopharmaceutical business leader with significant experience in drug delivery companies. As both a CEO and board member he has contributed greatly to advancing the business/corporate development programs of a number of companies which held promising technology but needed commercial expertise. We are truly pleased to have Steve join our board — he brings a wealth of industry knowledge and the ability to position companies to achieve commercial success. All of this will be valuable as we advance our Dance 501 inhaled insulin product through late stage clinical trials and toward commercialization. He understands the importance of bringing forward the best user-friendly, cost-effective technologies in treating diabetes, a far too prevalent disease.”
Thornton said, “I’m excited to be joining the Dance board. I share the passion of John Patton and his team to bring pain free, lower cost, patient-connected technology to the treatment of diabetes. Inhaled insulin makes this important therapy more accessible for patients who have delayed initiation of insulin because of dislike of injections. I have been an investor at each stage in the company’s development.”
Read the Dance Biopharm press release.
